Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications
Table 5
Clinical trials of cartilage repair with UC-MSCs or their secretome.
Pathology
Source
Study design
Delivery mode
Patients (N°)
Results
Ref.
OA
Human UC-MSCs
Randomized, double-blind, controlled phase I/II
Intra-articular injection of UC-MSCs once or twice vs. HA injection
29
Double injection group showed significant amelioration of pain and disability at 6 and 12 months of follow-up compared to HA group. No severe adverse events were reported.
Single-center, investigator-initiated, retrospective study
Inta-articular injection of 100 mg of AM/UC particulate
42
Significant clinical improvement of pain and function in patients with moderate to severe knee OA, with the potential to delay total knee replacement for up to 12 months
Lower levels of serological markers ESR, CRP, RF at 1 and 3 years and anti-CCP at 3 years after treatment. Decrease of health and joint function indexes 1 and 3 years after treatment.
Intravenous drip of UC-MSCs and intravenous injection of 24 mg of cervus and cucumis peptides
119
Significant reduction of serological markers ESR, CRP, RF, and anti-CCP and improvement of health index and joint function index 1 year after treatment
Intravenous infusion of cells/kg of body weight with or without a single intramuscular infusion of 1 million IU of IFN-γ
63
Efficacy and ACR20 response rates attained in 53.3% patients with UC-MSCs alone and in 93.3% patients with UC-MSCs combined with IFN-γ at 3-month follow-up. No new or unexpected safety issues in 1-year follow-up
